MEDIROM Mother Labs Partners with TD SYNNEX to Accelerate National Adoption of "MOTHER Bracelet" and "REMONY"

Rhea-AI Summary

MEDIROM (NASDAQ: MRM) announced on December 4, 2025 that its subsidiary MOTHER Labs signed a distributor agreement with TD SYNNEX to accelerate nationwide rollout of the recharge-free smart tracker MOTHER Bracelet and the remote monitoring system REMONY.

The partnership will leverage TD SYNNEX's nationwide sales network, global distribution experience and prior track record introducing smart trackers in Japan. MOTHER Bracelet measures five metrics 24/7 without charging, while REMONY pairs the bracelet with a gateway for automatic data sync and real-time centralized monitoring.

Positive

• Signed distributor agreement with TD SYNNEX on December 4, 2025
• Access to TD SYNNEX nationwide sales network in Japan
• MOTHER Bracelet provides 24/7 recharge-free vital-data capture
• REMONY enables automatic data synchronization and centralized monitoring

Negative

• No financial terms or revenue impact disclosed in the agreement
• Potential commercial dependence on a single distributor partner
• No launch timetable or sales targets specified for nationwide rollout

Key Figures

Global network reach more than 100 countries TD SYNNEX solution aggregator network

Manufacturer partners over 1,500 manufacturers TD SYNNEX partnerships

Health metrics tracked 5 metrics MOTHER Bracelet health data (heart rate, calories, temperature, steps, sleep)

Monitoring duration 24/7 Recharge-free continuous tracking by MOTHER Bracelet and REMONY

Market Reality Check

$2.14 Last Close

Volume Volume 78,721 is 34% above the 20-day average of 58,859. high

Technical Trading above 200-day MA, with price $2.14 vs 200-day MA $1.45.

Peers on Argus

No peers from the Personal Services group appeared in the momentum scanner, suggesting the reaction was stock-specific rather than a sector-wide move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Oct 30	Internal financing	Positive	+7.7%	Series A capital investment into MOTHER Labs by internal management.
Oct 29	Crypto treasury move	Negative	-21.0%	Adoption of cryptocurrency holdings as part of treasury strategy.
Oct 28	World ID milestone	Positive	-1.5%	Surpassing 10,000 World ID verifications at wellness salons.
Oct 09	Series A valuation	Positive	+3.5%	Approval of Series A round at ¥9 billion valuation for MOTHER Labs.
Sep 25	World partnership	Positive	-7.0%	Decision to double deployment of World ID Orb devices to 200 stores.

Pattern Detected

News tied to strategic investments and partnerships has produced mixed reactions, with some capital and expansion updates seeing gains while crypto-related and certain partnership news saw notable declines.

Recent Company History

Over the last few months, MEDIROM reported several strategic developments, including internal Series A investments in MOTHER Labs at a ¥9 billion valuation and expansion of its health-tech offerings. It also pursued a new cryptocurrency treasury strategy and scaled World ID verification and Orb device installations across up to 200 locations. Market reactions have been mixed, with some growth-oriented updates drawing positive moves and others, notably the crypto strategy and a prior partnership announcement, seeing negative follow-through. This partnership fits into the company’s broader tech-enabled wellness expansion.

Historical Comparison

partnership

+7.0 %

Average Historical Move

Historical Analysis

In the past 6 months, MRM had 1 partnership headline, linked to Orb deployment, with an average move of -7.05%. Today’s partnership with TD SYNNEX adds another distribution-focused agreement to this theme.

Typical Pattern

Partnership strategy has evolved from in-store Orb deployments toward broader distribution of MOTHER Bracelet and REMONY via TD SYNNEX.

Regulatory & Risk Context

Short Interest

6.28%

0% 15% 30%+

moderate

Short interest at 6.28% of float with 1 day to cover indicates a moderate level of bearish positioning but not an extreme crowding risk.

Market Pulse Summary

The stock is down -9.6% following this news. A negative reaction despite partnership news would fit the mixed pattern seen in past announcements, where a prior partnership update coincided with a -7.05% move. Investors have also reacted sharply to strategic shifts such as the crypto treasury decision (-20.99%). With short interest at 6.28% of float, downside could be reinforced by bearish positioning if confidence in execution or commercial impact remains uncertain.

Key Terms

distributor agreement financial

"has entered into a distributor agreement (the “Agreement”) with TD SYNNEX"

A distributor agreement is a formal arrangement where one party grants another the right to sell or distribute its products or services. It functions like a partnership where the distributor helps reach more customers, similar to a store selling products on behalf of a manufacturer. For investors, it indicates how a company plans to expand its reach and generate sales through external partners.

remote health monitoring system medical

"the remote health monitoring system “REMONY®,” both developed by MOTHER Labs"

A remote health monitoring system is a technology that allows medical data from a person, such as heart rate or blood pressure, to be collected and sent to healthcare providers from a distance, often using wearable devices or sensors. For investors, it represents a growing industry focused on improving healthcare efficiency and patient outcomes through technology, potentially leading to new business opportunities and market growth.

Seebeck effect technical

"tracker utilizing the Seebeck effect (as of July 3, 2021, based on ESP Research)"

The Seebeck effect occurs when a temperature difference between two different metals or materials creates an electrical voltage. Imagine one end of a metal is heated while the other stays cool; this temperature difference causes electrons to move, generating a small electric current. Understanding this effect is important for designing temperature sensors and energy-harvesting devices, which can impact various technologies and industries.

AI-generated analysis. Not financial advice.

TOKYO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) today announced that its subsidiary, MEDIROM MOTHER Labs Inc. (“MOTHER Labs”), which develops health-tech solutions, has entered into a distributor agreement (the “Agreement”) with TD SYNNEX K.K. (“TD SYNNEX”).

Through the execution of the Agreement, MOTHER Labs will collaborate with TD SYNNEX to leverage its nationwide sales network and extensive expertise in IT product distribution, with the aim of accelerating the nationwide expansion of the recharge-free smart tracker “MOTHER Bracelet®” and the remote health monitoring system “REMONY®,” both developed by MOTHER Labs.

• ︎Partnership Initiatives
  TD SYNNEX is a solution aggregator with a global network spanning more than 100 countries and partnerships with over 1,500 manufacturers, leveraging its extensive product portfolio to deliver optimized solutions that combine both domestic and international IT products. TD SYNNEX also has a proven track record of successfully expanding the adoption of overseas smart trackers in the Japanese market as an authorized distributor. As a partner company of MOTHER Labs, the two organizations will continue to collaborate closely to further promote the nationwide implementation of health management and safety solutions.
  
  
• MOTHER Bracelet®︎, Recharge-Free Smart Tracker

MOTHER Bracelet®︎ is the world's first* 24/7 recharge-free smart tracker, powered by advanced technology from a Silicon Valley-based tech business that generates electricity from the temperature difference between the body and the surrounding air. As it doesn't require recharging, it eliminates the data loss that can occur when a device is taken off for charging. This single device can record five fundamental health metrics: heart rate, calories burned, body surface temperature, step count, and sleep.

Official Website: https://mother-bracelet.com

• WPO, PATENTSCOPE, the Japan Science and Technology Agency, J-GLOBAL, and J-PlatPat have confirmed intellectual property related to recharge-free activity tracker utilizing the Seebeck effect (as of July 3, 2021, based on ESP Research)

• REMONY, Remote Health Monitoring System

'REMONY', a remote health monitoring system, developed by MOTHER Labs, combines the wrist-worn recharge-free smart tracker MOTHER Bracelet with a dedicated gateway. The system enables automatic data synchronization and centralized real-time management. Health monitoring with conventional wearables often faces challenges due to data loss during the device recharge period. However, MOTHER Bracelet measures user vital data in real-time 24/7 without needing removal for recharging. As a result, it allows for prompt and early detection of health emergencies and accident prevention with high accuracy. The system is customizable for use in various industries, including elder care, health monitoring for night shift workers, etc.

Features:
-  Measurement and display of heart rate, calories burned, body surface temperature, step count and sleep
-  Various alert functions (fall detection, abnormal heart rate, heatstroke, SOS call, etc.)
-  Automatic notification functions linked to alerts

Company Overview

• ABOUT MEDIROM MOTHER Labs Inc.

MOTHER Labs is a subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) with a focus on the health-tech sector. The company’s core activities include the “Specific Health Guidance Program” offered through the “Lav” health application and the development and sales of the 24/7 recharge-free MOTHER Bracelet smart tracker. By leveraging the features of the recharge-free MOTHER Bracelet, MOTHER Labs offers customizable health management solutions across diverse sectors, including caregiving, logistics, manufacturing, etc.

In addition, through the operation of “Re.Ra.Ku PRO,” a running station designed to support the health management of runners, the company provides healthcare services that integrate real-world engagement with technology.

MEDIROM Healthcare Technologies Inc.
NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Web https://medirom.co.jp/en
Contact: ir@medirom.co.jp

• Forward-Looking Statements Regarding MEDIROM
  Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about MEDIROM’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to MEDIROM’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause MEDIROM’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond MEDIROM’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects MEDIROM’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MEDIROM’s operations, results of operations, growth strategy and liquidity. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release include:
  
  
• MEDIROM’s ability to achieve its development goals for its business and execute and evolve its growth strategies, priorities and initiatives;
• changes in Japanese and global economic conditions and financial markets, including their effects on MEDIROM’s expansion in Japan and certain overseas markets;
• MEDIROM’s ability to achieve and sustain profitability in its Digital Preventative Healthcare Segment;
• the fluctuation of foreign exchange rates, which affects MEDIROM’s expenses and liabilities payable in foreign currencies;
• MEDIROM’s ability to maintain and enhance the value of its brands and to enforce and maintain its trademarks and protect its other intellectual property;
• MEDIROM’s ability to raise additional capital on acceptable terms or at all;
• MEDIROM’s level of indebtedness and potential restrictions on MEDIROM under MEDIROM’s debt instruments;
• changes in consumer preferences and MEDIROM’s competitive environment;
• MEDIROM’s ability to respond to natural disasters, such as earthquakes and tsunamis, and to global pandemics, such as COVID-19; and
• the regulatory environment in which MEDIROM operates.

More information on these risks and other potential factors that could affect MEDIROM’s business, reputation, results of operations, financial condition, and stock price is included in MEDIROM’s filings with the Securities and Exchange Commission (the “SEC”), including in the “Risk Factors” and “Operating and Financial Review and Prospects” sections of MEDIROM’s most recently filed periodic report on Form 20-F and subsequent filings, which are available on the SEC website at www.sec.gov. MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/fe27b4a2-ae33-44e4-b271-767190f3cc90

https://www.globenewswire.com/NewsRoom/AttachmentNg/713473e2-5357-403d-afbe-b05ca5a61212

https://www.globenewswire.com/NewsRoom/AttachmentNg/aa7709e3-6b71-4fa5-b861-52b99eace455

https://www.globenewswire.com/NewsRoom/AttachmentNg/7312d7e3-d492-46fd-81a4-5225b40a251f

https://www.globenewswire.com/NewsRoom/AttachmentNg/fb1a710d-7d59-4419-becd-69e6648c1ac4

FAQ

What did MEDIROM (MRM) announce on December 4, 2025?

MEDIROM said its subsidiary MOTHER Labs signed a distributor agreement with TD SYNNEX to expand MOTHER Bracelet and REMONY nationwide.

How will TD SYNNEX support MOTHER Labs' rollout for MRM?

TD SYNNEX will use its nationwide sales network and IT distribution expertise to promote product adoption across Japan.

What metrics does the MOTHER Bracelet record for MRM products?

MOTHER Bracelet records heart rate, calories burned, body surface temperature, step count and sleep continuously.

What is REMONY and how does it work for MRM solutions?

REMONY pairs the MOTHER Bracelet with a dedicated gateway for automatic data sync and centralized real-time health monitoring.

Does the MRM announcement disclose financial terms or sales targets?

No; the press release does not disclose financial terms, pricing, or specific sales targets.

Why is recharge-free operation significant for MOTHER Bracelet (MRM)?

Recharge-free operation aims to prevent data loss from device removal by enabling 24/7 continuous measurement.